AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Core Insights - AIM ImmunoTech will participate in the Virtual Investor Closing Bell Series on December 4, 2025, featuring CEO Thomas K. Equels [1] - The discussion will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, particularly the DURIPANC clinical trial in collaboration with AstraZeneca for metastatic pancreatic cancer [2] - The importance of a completed Phase 2 clinical trial with Merck, showing the combination of Ampligen and Keytruda was well-tolerated and beneficial for advanced recurrent ovarian cancer, will also be highlighted [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]